Dupilumab and Lymphoma Risk in AD? - Top-Institutions - MDSpire

Dupilumab and Lymphoma Risk in AD?

Dupilumab is safe from a lymphoma-risk perspective in atopic dermatitis and other type 2 inflammatory diseases, based on real-world data.

  • By

  • Julia Cipriano, MS, CMPP

  • February 9, 2026

  • 3 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Immunology
    • Dermatology
    • Clinical Research

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Oncology
    • Immunology

  • #3

    University of Lübeck
    University of Lübeck

    Lübeck, Schleswig-Holstein

    Key Differentiators

    • Dermatology
    • Clinical Epidemiology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Hematology
    • Immunology

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology
    • Oncology

Original Source(s)

Dupilumab and Lymphoma Risk in AD?

  • by Julia Cipriano, MS, CMPP

  • February 9, 2026

Related Content

Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Ketamine versus propofol for procedural sedation in pediatric pulsed dye laser therapy: a prospective randomized trial